Member Info for bluesky687

Olderandwiser? news on Blautix were expected Q3, now can pop up anytime. releasing these words on the 30th (added below) and talking about a potential poor RNS is nonsense

"Developing a new approach to IBS

4D pharma is conducting the world's largest clinical trial of a Live Biotherapeutic to date with its Phase II trial of Blautix® for the treatment of irritable bowel syndrome (IBS).

In April, the Company announced the successful completion of an interim futility analysis of the trial on a total of 118 IBS-C (constipation-predominant) and 128 IBS-D (diarrhoea-predominant) patients. This pre-specified interim analysis was not designed to quantify interim results, only to demonstrate that the study was not futile with respect to the primary endpoint. The interim analysis achieved its limited objective, and 4D pharma was encouraged to continue the analysis of the full trial data.

Moreover, Blautix was shown to have a safety profile comparable to placebo, with 3% and 2% patient discontinuation due to adverse events in the Blautix® and placebo arms respectively, and mild or moderate adverse events reported in 24% of subjects for both Blautix® and placebo arms.

The trial has now completed enrolment of approximately 370 patients and 4D pharma expects to announce full topline results in the first few days in Q4. Blautix® has the potential to be the world's first disease modifying therapy for IBS, by treating the underlying microbiome cause of disease. "

correct noix - DDDD is developing a new approach to IBS

from RNS earlier this year - in my view clear statements to consider for upcoming or lets say expected RNS ref. Blautix
Fri, 17th Apr 2020 07:00
RNS Number : 9582J
4d Pharma PLC
17 April 2020

"The interim analysis of the Blautix phase II results in IBS is encouraging," says Dr. Alex Stevenson, Chief Scientific Officer, 4D Pharma. "IBS is a disease that causes significant morbidity and has a high unmet medical need. 4D Pharma identified the potential of the live biotherapeutic Blautix as a new approach to treat IBS and address both IBS-C and IBS-D with the same therapy. The interim analysis supports and informs 4D Pharma's future development and commercialisation plans with partners."

where?

what a great year for dddd + further readouts expected. purely amazing

https://twitter.com/4dpharmaplc/status/1310515499609010176

"Great to see Dr Katrin Rupalla’s appointment as an independent non-executive director covered in @Endpoints
. We are delighted to have Katrin join the @4dpharmaplc
#DDDD $DDDD team."

https://www.4dpharmaplc.com/en/developing-science/pipeline

Current pipeline
Using MicroRx®, we have generated a suite of development programmes in diverse therapeutic areas including immuno-oncology, GI, respiratory, autoimmune and CNS disease.

also topped up

look at the 3month chart and turn around your screen donotpanic

Have just seen it on their web page, not sure if posted already

https://www.4dpharmaplc.com/en/investors/reports-presentations

:D or no worries

now worries :)

https://www.4dpharmaplc.com/en/newsroom/press-releases/clinical-update-interim-analysis-blautix-phase-ii

watching patiently

out

Fingers crossed Monday the latest

Could be.

who cares if one is sarcastic or supportive. with those interesting projects, potential is there for sure. if POW will deliver or not is most probably a question you will not get an answer for within a few weeks. things take time. depending on how you look at it, there are plenty of good and bad examples out there.

4d Pharma PLC
29 November 2019

Position of previous notification (if

applicable)

13.51%

Resulting situation on the date on which threshold was crossed or reached

14.75%

Patience is needed. Relax a little